XCL1 and neoplasm: In view of the potent antitumor activity of Xcl1 fusion proteins observed in the EG7 tumor model, we assessed the tumor protective immunity of the Xcl1-mediated tumor vaccine in the less immunogenic B16-OVA melanoma tumor model.